Table 2 Baseline serum oxylipin metabolite profiles in patients with stable coronary artery disease who encountered acute myocardial infarction during follow-up (Subject group) and in the patients without cardiovascular events during follow-up (Control group).

From: Association of Arachidonic Acid-derived Lipid Mediators with Subsequent Onset of Acute Myocardial Infarction in Patients with Coronary Artery Disease

Substrate

Catalytic enzyme

Oxylipin (ng/mL)

Control group (n = 50)

Subject group (n = 25)

P value

LA; ω-6

LOXs

9-HODE

14.53 ± 18.29

10.53 ± 6.41

0.216

9-oxoODE

0.65 ± 0.08

0.69 ± 0.13

0.164

9,10,13-TriHOME

1.14 ± 0.34

1.29 ± 0.60

0.257

9,12,13-TriHOME

1.20 ± 1.41

1.05 ± 0.43

0.480

13-HODE

21.01 ± 17.33

20.16 ± 12.26

0.813

13-oxoODE

0.72 ± 0.16

0.75 ± 0.16

0.439

CYPs

9,10-EpOME

14.73 ± 14.21

11.14 ± 6.27

0.169

12,13-EpOME

20.40 ± 16.15

20.36 ± 11.40

0.991

CYPs-sEH

9,10-DHOME

7.17 ± 8.56

5.66 ± 5.15

0.351

12,13-DHOME

1.48 ± 1.06

1.45 ± 0.86

0.893

AA; ω-6

LOXs

5-HETE

4.55 ± 0.62

4.63 ± 0.48

0.529

5-oxoETE

4.48 ± 0.55

4.72 ± 0.51

0.069

LTA4

280.25 ± 243.41

279.20 ± 235.88

0.986

LTB4

4.21 ± 0.37

4.16 ± 0.04

0.361

8-HETE

30.48 ± 42.97

88.35 ± 142.48

0.011

9-HETE

4.24 ± 0.19

4.52 ± 0.67

0.007

11-HETE

4.51 ± 0.38

5.38 ± 1.66

0.001

12-HETE

19.08 ± 25.39

55.99 ± 87.64

0.009

15-HETE

30.63 ± 42.31

91.48 ± 145.66

0.009

15-oxoETE

4.16 ± 0.04

4.16 ± 0.05

0.860

LXA4

4.13 ± 0.00

4.13 ± 0.01

0.338

LXB4

4.47 ± 0.21

4.48 ± 0.27

0.942

CYPs

19-HETE

6.41 ± 3.19

12.64 ± 12.29

0.001

20-HETE

8.44 ± 5.93

18.95 ± 21.70

0.003

5,6-EET

40.26 ± 31.06

79.12 ± 99.03

0.015

8,9-EET

26.71 ± 13.14

43.10 ± 34.93

0.005

11,12-EET

68.37 ± 43.73

171.77 ± 203.83

0.001

14,15-EET

38.68 ± 17.78

69.53 ± 67.05

0.004

CYPs-sEH

5,6-DHET

20.76 ± 0.49

20.85 ± 0.49

0.456

8,9-DHET

20.97 ± 0.51

20.99 ± 0.60

0.894

11,12-DHET

27.23 ± 6.06

29.76 ± 9.31

0.169

14,15-DHET

36.80 ± 9.55

43.37 ± 23.12

0.094

THF-diols

20.71 ± 0.28

20.63 ± 0.13

0.148

COXs

PGE2/PGD2

0.07 ± 0.01

0.07 ± 0.00

0.152

PGB2/PGJ2

0.07 ± 0.00

0.07 ± 0.00

0.837

15-deoxy-PGJ2

0.09 ± 0.03

0.09 ± 0.02

0.937

6-keto-PGF1α

0.07 ± 0.00

0.07 ± 0.00

0.931

PGF2α

0.07 ± 0.00

0.07 ± 0.00

0.704

TXB2

0.07 ± 0.02

0.08 ± 0.03

0.475

EPA; ω-3

  

114.86 ± 100.70

106.17 ± 94.60

0.716

LOXs

15-HEPE

161.12 ± 69.18

155.45 ± 72.28

0.747

DHA; ω-3

  

2341.65 ± 1424.61

2074.06 ± 1612.37

0.496

LOXs

17-HDHA

137.19 ± 135.15

216.64 ± 231.91

0.085

10,17-DiHDHA

5.51 ± 0.03

5.52 ± 0.03

0.157

Resolvin D1

5.50 ± 0.01

5.51 ± 0.03

0.203

Maresin

5.60 ± 0.21

5.49 ± 0.01

0.252

  1. AA, arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; CYP-sEH, cytochrome P450-soluble epoxide hydrolase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; LOX, lipoxygenase; sEH, soluble epoxide hydrolase.
Back to article page